A Turkish 3-center study evaluation of serum folic acid and vitamin B12 levels in Alzheimer disease

Background/aim: Alzheimer disease, a common proteopathy of advanced age, is characterized by cortical atrophy, neuron degeneration, neuronal loss, and accumulation of extracellular amyloid β plaques. We aimed to investigate serum vitamin B12 and folic acid levels in Alzheimer disease and other dementia patients, as a potential screening test to detect presymptomatic Alzheimer disease in Turkish patients. Materials and methods: We evaluated folic acid and vitamin B12 levels in Alzheimer disease patients as well as in other dementia and geriatric patients from Ankara, Dokuz Eylül, and Çukurova university hospitals; 290 female and male geriatric subjects were enrolled. Vitamin B12 and folic acid levels were measured using Roche E170 and Beckman Coulter DXI 800 immunoassays (chemiluminescence) according to the manufacturers' guideline in all centers. Results: We evaluated the results of folic acid and vitamin B12 in Alzheimer disease, other dementias and geriatric patients. No significant difference between the groups regarding the routine control of biochemical parameters was observed. Conclusion: Currently, serum folic and vitamin B12 levels are not diagnostically reliable tests for screening presymptomatic Alzheimer disease. However, the results may statistically be significant if we increase the sample size.

A Turkish 3-center study evaluation of serum folic acid and vitamin B12 levels in Alzheimer disease

Background/aim: Alzheimer disease, a common proteopathy of advanced age, is characterized by cortical atrophy, neuron degeneration, neuronal loss, and accumulation of extracellular amyloid β plaques. We aimed to investigate serum vitamin B12 and folic acid levels in Alzheimer disease and other dementia patients, as a potential screening test to detect presymptomatic Alzheimer disease in Turkish patients. Materials and methods: We evaluated folic acid and vitamin B12 levels in Alzheimer disease patients as well as in other dementia and geriatric patients from Ankara, Dokuz Eylül, and Çukurova university hospitals; 290 female and male geriatric subjects were enrolled. Vitamin B12 and folic acid levels were measured using Roche E170 and Beckman Coulter DXI 800 immunoassays (chemiluminescence) according to the manufacturers' guideline in all centers. Results: We evaluated the results of folic acid and vitamin B12 in Alzheimer disease, other dementias and geriatric patients. No significant difference between the groups regarding the routine control of biochemical parameters was observed. Conclusion: Currently, serum folic and vitamin B12 levels are not diagnostically reliable tests for screening presymptomatic Alzheimer disease. However, the results may statistically be significant if we increase the sample size.

___

  • Berchtold NC, Cotman CW. Evolution in the conceptualization of dementia and Alzheimer’s disease: Greco-Roman Period to the 1960s. Neurobiol Aging 1998; 19: 173–189.
  • Thies W, Bleiler L. Alzheimer’s Association. Alzheimer’s disease facts and figures. Alzheimers Dement 2013; 9: 208–245.
  • Guidolin D, Agnati LF, Albertin G, Tortorella C, Fuxe K. Bioinformatics aggregation predictors in the study of protein conformational diseases of the human nervous system. Electrophoresis 2012; 33: 3669–3679.
  • Mayeux R, Stern Y. Epidemiology of Alzheimer disease. Cold Spring Harb Perspect Med 2012; 2: 1–26.
  • Tatar M, Mollahaliloğlu S, Sahin B, Aydin S, Maresso A, Hernández-Quevedo C. Health system review. Health systems in transition Turkey 2011; 13: 1–186.
  • Sambamurti K, Greig NH, Utsuki T, Barnwell EL, Sharma E, Mazell C, Bhat NR, Kindy MS, Lahiri DK, Pappolla MA. Targets for AD treatment: conflicting messages from γ-secretase inhibitors. J Neurochem 2011; 117: 359–374.
  • Fändrich M, Schmidt M, Grigorieff N. Recent progress in understanding Alzheimer’s β-amyloid structures. Trends Biochem Sci 2011; 36: 338–345.
  • Yu QS, Reale M, Kamal MA, Holloway HW, Luo W, Sambamurti K, Ray B, Lahiri DK, Rogers JT et al. Synthesis of the Alzheimer drug Posiphen into its primary metabolic products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)- N1, N8-bisnorPosiphen, their inhibition of amyloid precursor protein, α-Synuclein synthesis, interleukin-1β release, and cholinergic action. Antiinflamm Antiallergy Agents Med Chem 2013; 12: 117–128.
  • Shin RW, Ogomori K, Kitamoto T, Tateishi J. Increased tau accumulation in senile plaques as a hallmark in Alzheimer’s disease. Am J Pathol 1989; 134: 1365–1371.
  • Yu J, Gattoni-Celli M, Zhu H, Bhat NR, Sambamurti K, Gattoni- Celli S, Kindy MS. Vitamin D3-enriched diet correlates with a decrease of amyloid plaques in the brain of AβPP transgenic mice. J Alzheimers Dis 2011; 25: 295–307.
  • Blennow K, de Leon MJ, Zetterberg H. Alzheimer’s disease. Lancet 2006; 368: 387–403.
  • Noble W, Pooler AM, Hanger DP. Advances in tau-based drug discovery. Expert Opin Drug Discov 2011; 6: 797–810.
  • Koppel J, Acker C, Davies P, Lopez OL, Jimenez H, Azose M, Greenwald BS, Murray PS, Kirkwood CM, Kofler J et al. Psychotic Alzheimer’s disease is associated with gender- specific tau phosphorylation abnormalities. Neurobiol Aging 2014; 35: 2021–2028.
  • Humpel C. Identifying and validating biomarkers for Alzheimer’s disease. Trends Biotechnol 2011; 29: 26–32.
  • Ulusu NN, Tandogan B, Tezcan FE. Kinetic properties of glucose-6-phosphate dehydrogenase from lamb kidney cortex. Biochimie 2005; 87: 187–190.
  • Ulusu NN, Tandogan B. Purification and kinetics of sheep kidney cortex glucose-6-phosphate dehydrogenase. Comp Biochem Physiol B: Biochem Mol Biol 2006; 143: 249–255.
  • Bilkei-Gorzo A. Genetic mouse models of brain ageing and Alzheimer’s disease (Review). Pharmacol Ther 2014; 142: 244– 257.
  • Raz N, Gunning FM, Head D, Dupuis JH, Mc Quain J, Briggs SD, Loken WJ, Thornton AE, Acker JD. Selective aging of human cerebral cortex observed in vivo: differential vulnerability of the prefrontal gray matter. Cereb Cortex 1997; 7: 268–282.
  • Fjell AM, Westlye LT, Amlien I, Espeseth T, Reinvang I, Raz N, Agartz I, Salat DH, Greve DN, Fischl B et al. High consistency of regional cortical thinning in aging across multiple samples. Cereb Cortex 2009; 19: 2001–2012.
  • Gillette-Guyonnet S, Van Kan GA, Andrieu S, Barberger- Gateau P, Berr C, Bonnefoy, M, Dartigues JF, De Groot L, Ferry M, Galan P et al. IANA task force on nutrition and cognitive decline with aging. J Nutr Health Aging 2007; 11: 132–152.
  • Sreeja V, Jana A, Aparnathi K, Prajapati J. Role of whey proteins in combating geriatric disorders. J Sci Food Agr 2013; 93: 3662–3669.
  • Nicklett EJ1, Kadell AR. Fruit and vegetable intake among older adults: a scoping review. Maturitas 2013; 75: 305–312.
  • Banerjee R, Ragsdale SW. The many faces of vitamin B12: catalysis by cobalamin-dependent enzymes. Annu Rev Biochem 2003; 72: 209–247.
  • Selhub J, Paul L. Folic acid fortification: why not vitamin B12 also? Biofactors. 2011; 37: 269–271.
  • Cacciapuoti F. Lowering homocysteine levels with folic acid and B-vitamins do not reduce early atherosclerosis, but could interfere with cognitive decline and Alzheimer’s disease. J Thromb Thrombolysis 2013; 36: 258–262.
  • Larson EB, Kukull WA, Katzman RL. Cognitive impairment: dementia and Alzheimer’s disease. Annu Rev Public Health 1992; 13: 431–449.
  • Douaud G, Refsum H, de Jager CA, Jacoby R, Nichols TE, Smith SM, Smith AD. Preventing Alzheimer’s disease-related gray matter atrophy by B-vitamin treatment. P Natl Acad Sci USA 2013; 110: 9523–9528.
  • Mattson MP, Shea TB. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci 2003; 26: 137–146.
Turkish Journal of Medical Sciences-Cover
  • ISSN: 1300-0144
  • Yayın Aralığı: Yılda 6 Sayı
  • Yayıncı: TÜBİTAK
Sayıdaki Diğer Makaleler

Neurodegeneration in ocular and central nervous systems: optical coherence tomography study in normal-tension glaucoma and Alzheimer disease*

Muhsin ERASLAN, Eren ÇERMAN, Osman ÇEKİÇ, Sevcan BALCI, Volkan DERİCİOĞLU, Özlem ŞAHİN, Devran SÜER, Biman CHABOU, Emine Neşe Tuncer ELMACI

Cognitive problems related to vertebrobasilar circulation

Abdulkadir KOÇER

The effects and interactions of APOE and APH-1A polymorphisms in Alzheimer disease

Burcu Acar ÇİNLETİ, Nilgül YARDIMCI, Zübeyde AYTÜRK, Atilla İLHAN, Gülhan KAYA, Muradiye ACAR, Emine Rabia KOÇ, Esra GÜNDÜZ, Mehmet GÜNDÜZ

The reliability and validity of the Turkish version of theNeuropsychiatric Inventory-Clinician

Eylem Şahin CANKURTARAN, Mustafa DANIŞMAN, Hasan TUTAR, Semra Ulusoy KAYMAK

Postoperative cognitive dysfunction and Alzheimer disease

BERRİN IŞIK

The value of FDG-PET/CT by using 3-dimensional stereotactic surface projection software analysis in the differential diagnosis of dementia

Esra ARSLAN, Özgül EKMEKÇİOĞLU, Fatma Arzu GÖRTAN, Zeynep Funda Engin AKCAN, Melih Engin ERKAN, Haci Murat EMÜL, Metin HALAÇ, Tevfik Fikret ÇERMİK, Kerim SÖNMEZOĞLU

Forensic medicine evaluation of Alzheimer patients: a series from Ankara, Turkey

MEHMET CAVLAK, RAMAZAN AKÇAN, ALİ RIZA TÜMER, AYSUN BALSEVEN ODABAŞI, AYKUT LALE, MAHMUT ŞERİF YILDIRIM, EYUP RUŞEN HEYBET

Plasma 8-isoPGF2? and serum melatonin levels in patients with minimal cognitive impairment and Alzheimer disease

Fevziye Burcu ŞİRİN, Duygu Kumbul DOĞUÇ, Hüseyin VURAL, İbrahim EREN, İkbal İNANLI, Recep SÜTCÜ, Namik DELİBAŞ

Preface - Special Issue on: Alzheimer Disease: From Bench to Bedside'

MARK S KINDY, ÖMER AKYOL, KUMAR SAMBAMURTI

Nerve growth factor receptors in dementia

Manoochehr MESSRIPOUR, Abolfazl NAZARIAN, Azadeh MESRIPOUR, İman MOHAMMADI